Results 51 to 60 of about 35,120,764 (296)

Plant Programmed Cell Death Methods [PDF]

, 2020
Programmed cell death (PCD) is a critical component of plant development, defense against invading pathogens, and response to environmental stresses.
Gunawardena, Arunika H. L. A. N., McCabe, Paul F., Gallois, Patrick, Kacprzyk, Joanna, Dauphinee, Adrian N.   +4 more
core   +1 more source

CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling [PDF]

, 2009
CD95 is a multifunctional receptor that induces cell death or proliferation depending on the signal, cell type, and cellular context. Here, we describe a thus far unknown function of CD95 as a silencer of T cell activation.
Lindquist, Jonathan, Strauss, Gudrun, Lindquist, Jonathan A., Arhel, Nathalie, Nathalie Arhel, Tobias L. Haas, Edward Felder, Fulda, Simone, Haas, Tobias L., Henning Walczak, Felder, Edward, Kirchhoff, Frank, Gudrun Strauss, Sabine Karl, Simone Fulda, Walczak, Henning, Karl, Sabine, Frank Kirchhoff, Klaus-Michael Debatin, Debatin, Klaus-Michael, Jonathan A. Lindquist, Haas, Tobias   +21 more
core   +1 more source

Bloodstream form trypanosoma brucei depend upon multiple metacaspases associated with RAB11-positive endosomes [PDF]

, 2006
Trypanosoma brucei possesses five metacaspase genes. Of these, MCA2 and MCA3 are expressed only in the mammalian bloodstream form of the parasite, whereas MCA5 is expressed also in the insect procyclic form.
Appleton, Paul, Ambit, Audrey, Helms, Matthew J., Tetley, Laurence, Mottram, Jeremy C., Coombs, Graham H.   +5 more
core   +4 more sources

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Organizing the interface—Plasma membrane architecture and receptor dynamics in virus‐cell interactions

FEBS Letters, EarlyView.
Plasma membranes contain dynamic nanoscale domains that organize lipids and receptors. Because viruses operate at similar scales, this architecture shapes early infection steps, including attachment, receptor engagement, and entry. Using influenza A virus and HIV‐1 as examples, we highlight how receptor nanoclusters, multivalent glycan interactions ...
Jan Schlegel, Christian Sieben
wiley   +1 more source

From mice to humans—divergent strategies for intestinal homeostasis and regeneration

FEBS Letters, EarlyView.
Recent advances such as organoid genome editing, xenotransplantation, imaging, and whole‐genome sequencing have enabled direct studies of human intestinal stem cells (ISCs). These studies reveal species‐specific features, including slower ISC proliferation, distinct injury responses, slower somatic mutation accumulation in humans, and an inverse ...
Keiko Ishikawa, Shinya Sugimoto, Toshiro Sato   +2 more
wiley   +1 more source

Structural insights and therapeutic targets in Acinetobacter baumannii capsule biosynthesis

FEBS Letters, EarlyView.
Hypervirulent KL49 A. baumannii's capsular polysaccharide contains the nonulosonic acid 8‐epi‐Leg5,7Ac2, synthesized by epimerization via ElaA, ElaB, and ElaC. Crystal structures of ElaA, ElaB, and ElaC reveal their role in CMP‐Leg5,7Ac2 synthesis and regioselective C8 epimerization.
Woo Cheol Lee, Junho Jeong, Chae Yeong Lee, Hyunjoon Cho, Man Hwan Oh, Je Chul Lee, Jee‐Young Lee, Yangmee Kim   +7 more
wiley   +1 more source

Present and Future of Efficacy Biomarkers in Immune Checkpoint Inhibitors 
of Small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2020
Inhibitions of immune checkpoints, including programmed cell death 1-programmed cell death-ligand 1 (PD-1-PD-L1) axis, cytotoxic T lymphocyte associated antigen-4, are at the forefront of immunotherapy for small cell lung cancer.
Yaning YANG, Yan WANG
doaj   +1 more source

Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Pathway in High-Risk Lymphocytic Acute Myocarditis

JACC: Advances
Background: The programmed cell death-1 (PD-1)/programmed cell death-ligand-1 (PD-L1) pathway is affected in immune checkpoint inhibitor (ICI)-associated acute myocarditis (AM), while this pathway in non-ICI-associated lymphocytic AM (LAM) is unexplored.
Enrico Ammirati, MD, PhD, Guglielmo Gallone, MD, Giacomo Veronese, MD, Eric D. Adler, MD, Mikko I. Mäyränpää, MD, Emanuela Bonoldi, MD, Duccio Petrella, MD, Paul J. Kim, MD, MAS, Michela Brambatti, MD, Matteo Pio Vaira, MD, Meike Rybczynski, MD, Hendrik Milting, MSc, PhD, Ina Michel-Behnke, MD, Fernando Gatto, MD, Florian Schlotter, MD, Holger Thiele, MD, Jose Benjamin Cruz Rodriguez, MD, MPH, Andreas Luchner, MD, Ulrich Grabmaier, MD, Steffen Massberg, MD, Herwig Schuchlenz, MD, Christian Ebner, MD, Tienush Rassaf, MD, Axel Linke, MD, Bettina Heidecker, MD, Tatiana Manuylova, MD, Andrea Garascia, MD, Javid J. Moslehi, MD, Jukka Y. Lehtonen, MD, Karin Klingel, MD   +29 more
doaj   +1 more source

Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications

American Journal of Ophthalmology, 2019
Novel cancer immunotherapies, called immune checkpoint inhibitors, have demonstrated clinical efficacy in the treatment of squamous cell carcinomas of the head and neck. Tissue expression of programmed cell death 1 ligand 1 (PD-L1) and programmed cell death 1 ligand 2 (PD-L2) has been shown to predict tumor response to these drugs.
Natalie, Wolkow, Frederick A, Jakobiec, Amir H, Afrogheh, Ralph C, Eagle, Sara I, Pai, William C, Faquin   +5 more
openaire   +3 more sources